Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays

ACS Chemical Biology

Volumn 12, Issue 5, 2017, Pages 1390-1396

  Nikiforov, Petar O ^a   Blaszczyk, Michal ^a   Surade, Sachin ^a   Boshoff, Helena I ^b   Sajid, Andaleeb ^b   Delorme, Vincent ^c   Deboosere, Nathalie ^c   Brodin, Priscille ^c   Baulard, Alain R ^c   Barry, Clifton E ^b,d   Blundell, Tom L ^a   Abell, Chris ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID; ETHIONAMIDE; ETHR PROTEIN; PROTEIN; SULFONAMIDE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; ENZYME INHIBITOR; ETHR PROTEIN, MYCOBACTERIUM TUBERCULOSIS; LIGAND; REPRESSOR PROTEIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL EFFECTIVENESS; CONCENTRATION PROCESS; DRUG DESIGN; DRUG EFFECT; DRUG SYNTHESIS; EX VIVO STUDY; IN VITRO STUDY; MOLECULAR SIZE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; WHOLE CELL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; MICROBIAL SENSITIVITY TEST;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DISCOVERY; DRUG SYNERGISM; ENZYME INHIBITORS; ETHIONAMIDE; LIGANDS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REPRESSOR PROTEINS;

EID: 85019649436     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.7b00091     Document Type: Article

References (21)

1. World Health Organization, Global tuberculosis report, (2015; http://www.who.int/tb/publications/global-report/gtbr2015-executive-summary.pdf.
2. World Health Organization, 2011/ 2012 tuberculosis global facts, (2011.
3. World Health Organization. Guidelines for treatment of tuberculosis, 4th ed.; WHO Press: Geneva, Switzerland, 2010.
4. Checkley, A. M. and McShane, H. (2011) Tuberculosis vaccines: progress and challenges Trends Pharmacol. Sci. 32, 601-606 10.1016/j.tips.2011.06.003
5. Anand, N., Upadhyaya, K., and Tripathi, R. P. (2015) Drug development pipeline for the treatment of tuberculosis: Needs, challenges, success and opportunities for the future Chem. Biol. Interface 5, 84-127
6. Koul, A., Arnoult, E., Lounis, N., Guillemont, N., and Andries, K. (2011) The challenge of new drug discovery for tuberculosis Nature 469, 483-490 10.1038/nature09657
7. Andries, K., Verhasselt, P., Guillemont, J., Goehlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmermann, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., and Jarlier, V. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307, 223-227 10.1126/science.1106753
8. Willand, N., Dirié, B., Carette, X., Bifani, P., Singhal, A., Desroses, M., Leroux, F., Willery, E., Mathys, V., Déprez-Poulain, R., Delcroix, G., Frénois, F., Aumercier, M., Locht, C., Villeret, V., Déprez, B., and Baulard, A. R. (2009) Synthetic EthR inhibitors boost antituberculous activity of ethionamide Nat. Med. 15, 537-544 10.1038/nm.1950
9. Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R., Jr., and Sacchettini, J. C. (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis Science 279, 98-102 10.1126/science.279.5347.98
10. Wang, F., Langley, R., Gulten, G., Dover, L. G., Besra, G. S., Jacobs, W. R., Jr., and Sacchettini, J. C. (2007) Mechanism of thioamide drug action against tuberculosis and leprosy J. Exp. Med. 204, 73-78 10.1084/jem.20062100
11. Bhatt, A., Molle, V., Besra, G. S., Jacobs, W. R., Jr., and Kremer, L. (2007) The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development Mol. Microbiol. 64, 1442-1454 10.1111/j.1365-2958.2007.05761.x
12. Zhang, Y., Heym, B., Allen, B., Young, D., and Cole, S. (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis Nature 358, 591-593 10.1038/358591a0
13. Engohang-Ndong, J., Baillat, D., Aumercier, M., Bellefontaine, F., Besra, G. S., Locht, C., and Baulard, A. R. (2004) EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator Mol. Microbiol. 51, 175-188 10.1046/j.1365-2958.2003.03809.x
14. Baulard, A. R., Betts, J. C., Engohang-Ndong, J., Quan, S., McAdam, R. A., Brennan, P. J., Locht, C., and Besra, G. S. (2000) Activation of the pro-drug ethionamide is regulated in mycobacteria J. Biol. Chem. 275, 28326-28331 10.1074/jbc.M003744200
15. DeBarber, A. E., Mdluli, K., Bosman, M., Bekker, L. G., and Barry, C. E., 3rd (2000) Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U. S. A. 97, 9677-9682 10.1073/pnas.97.17.9677
16. Flipo, M., Desroses, M., Lecat-Guillet, N., Dirié, B., Carette, X., Leroux, F., Piveteau, C., Demirkaya, F., Lens, Z., Rucktooa, P., Villeret, V., Christophe, T., Jeon, H. K., Locht, C., Brodin, P., Déprez, B., Baulard, A. R., and Willand, N. (2011) Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors J. Med. Chem. 54, 2994-3010 10.1021/jm200076a
17. Flipo, M., Desroses, M., Lecat-Guillet, N., Villemagne, B., Blondiaux, N., Leroux, F., Piveteau, C., Mathys, V., Flament, M.-P., Siepmann, J., Villeret, V., Wohlkönig, A., Wintjens, R., Soror, S. H., Christophe, T., Jeon, H. K., Locht, C., Brodin, P., Déprez, B., Baulard, A. R., and Willand, N. (2012) Ethionamide Boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors J. Med. Chem. 55, 68-83 10.1021/jm200825u
18. Villemagne, B., Flipo, M., Blondiaux, N., Crauste, C., Malaquin, S., Leroux, F., Piveteau, C., Villeret, V., Brodin, P., Villoutreix, B. O., Sperandio, O., Soror, S. H., Wohlkönig, A., Wintjens, R., Déprez, B., Baulard, A. R., and Willand, N. (2014) Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches J. Med. Chem. 57, 4876-4888 10.1021/jm500422b
19. Surade, S., Ty, N., Hengrung, N., Lechartier, B., Cole, S. T., Abell, C., and Blundell, T. L. (2014) A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR Biochem. J. 458, 387-394 10.1042/BJ20131127
20. Nikiforov, P. O., Surade, S., Blaszczyk, M., Delorme, V., Brodin, P., Baulard, A. R., Blundell, T. L., and Abell, C. (2016) A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters Org. Biomol. Chem. 14, 2318-2326 10.1039/C5OB02630J
21. Prideaux, B., Via, L. E., Zimmerman, M. D., Eum, S., Sarathy, J., O'Brien, P., Chen, C., Kaya, F., Weiner, D. M., Chen, P.-Y., Song, T., Lee, M., Shim, T. S., Cho, J. S., Kim, W., Cho, S. N., Olivier, K. N., Barry, C. E., III, and Dartois, V. (2015) The association between sterilizing activity and drug distribution into tuberculosis lesions Nat. Med. 21, 1223-1227 10.1038/nm.3937